
Ipsen S.A. – OTC:IPSEY
Ipsen S.A. stock price today
Ipsen S.A. stock price monthly change
Ipsen S.A. stock price quarterly change
Ipsen S.A. stock price yearly change
Ipsen S.A. key metrics
Market Cap | 8.64B |
Enterprise value | 8.96B |
P/E | 10.22 |
EV/Sales | 1.83 |
EV/EBITDA | 5.62 |
Price/Sales | 1.83 |
Price/Book | 2.21 |
PEG ratio | 0.10 |
EPS | N/A |
Revenue | N/A |
EBITDA | N/A |
Income | N/A |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 17.96% |
Oper. margin | 26.62% |
Gross margin | 81.8% |
EBIT margin | 26.62% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIpsen S.A. stock price history
Ipsen S.A. stock forecast
Ipsen S.A. financial statements
Dec 2022 | 1.59B | 254.3M | 15.98% |
---|---|---|---|
Jun 2023 | 1.53B | 195.2M | 12.7% |
Dec 2023 | 1.59B | 449.2M | 28.24% |
Mar 2024 | 0 | 0 |
2025 | 3.96B | 223.26M | 5.64% |
---|---|---|---|
2026 | 4.22B | 242.90M | 5.75% |
2027 | 4.55B | 273.23M | 6% |
2028 | 4.65B | 263.31M | 5.65% |
Analysts Price target
Financials & Ratios estimates
Payout ratio | 22.75% |
---|
2019 | 1.27% |
---|---|
2020 | 1.51% |
2021 | 1.21% |
2022 | 1.2% |
2023 | 4.29% |
Jun 2022 | 5507100000 | 2.44B | 44.32% |
---|---|---|---|
Dec 2022 | 5607900000 | 2.27B | 40.5% |
Jun 2023 | 6090600000 | 2.68B | 44.12% |
Dec 2023 | 6322900000 | 2.49B | 39.52% |
Jun 2022 | 419.8M | -178.6M | 40.9M |
---|---|---|---|
Dec 2022 | 533.4M | -280M | -186.9M |
Jun 2023 | 414.8M | -986M | -195.5M |
Dec 2023 | 428.5M | -86.2M | -240.3M |
Ipsen S.A. alternative data
Aug 2023 | 5,072 |
---|---|
Sep 2023 | 5,300 |
Oct 2023 | 5,300 |
Nov 2023 | 5,300 |
Dec 2023 | 5,300 |
Jan 2024 | 5,300 |
Feb 2024 | 5,300 |
Mar 2024 | 5,325 |
Apr 2024 | 5,325 |
May 2024 | 5,325 |
Jun 2024 | 5,325 |
Jul 2024 | 5,325 |
Ipsen S.A. other data
Quarter | Transcript |
---|---|
Q4 2022 9 Feb 2023 | Q4 2022 Earnings Call Transcript |
Q2 2022 30 Jul 2022 | Q2 2022 Earnings Call Transcript |
Q4 2021 11 Feb 2022 | Q4 2021 Earnings Call Transcript |
Q2 2021 2 Aug 2021 | Q2 2021 Earnings Call Transcript |
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Week In Review: Foreseen Sells ADC Rights To France's Ipsen In $1 Billion Deal
Genfit: Under The Radar Biotech With Upcoming Catalysts
Exelixis: With Patent Litigation Decision Due Soon, There Are Options
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Mirum Pharmaceuticals: Market Overreacts To Livmarli's Phase 2 Miss
CymaBay: Positive Phase 3 Data And Competitive Advantage Established
Hutchmed: Attractive Chinese R&D Giant
-
What's the price of Ipsen S.A. stock today?
One share of Ipsen S.A. stock can currently be purchased for approximately $32.38.
-
When is Ipsen S.A.'s next earnings date?
Unfortunately, Ipsen S.A.'s (IPSEY) next earnings date is currently unknown.
-
Does Ipsen S.A. pay dividends?
Yes, Ipsen S.A. pays dividends and its trailing 12-month yield is 1.3% with 23% payout ratio. The last Ipsen S.A. stock dividend of undefined was paid on 7 Sep 2025.
-
How much money does Ipsen S.A. make?
Ipsen S.A. has a market capitalization of 8.64B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 4.75% to 3.31B US dollars.
-
What is Ipsen S.A.'s stock symbol?
Ipsen S.A. is traded on the OTC under the ticker symbol "IPSEY".
-
What is Ipsen S.A.'s primary industry?
Company operates in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry.
-
How do i buy shares of Ipsen S.A.?
Shares of Ipsen S.A. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Ipsen S.A. have?
As Jul 2024, Ipsen S.A. employs 5,325 workers.
-
When Ipsen S.A. went public?
Ipsen S.A. is publicly traded company for more then 15 years since IPO on 8 Jun 2010.
-
What is Ipsen S.A.'s official website?
The official website for Ipsen S.A. is ipsen.com.
-
How can i contact Ipsen S.A.?
Ipsen S.A. can be reached via phone at +33 1 58 33 50 00.
Ipsen S.A. company profile:

Ipsen S.A.
ipsen.comOTC
5,000
Drug Manufacturers—Specialty & Generic
Healthcare
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.
Boulogne-Billancourt, 92100
:
ISIN: US4626292050
: